XTL Biopharmaceuticals Ltd (XTLB) - Total Assets
Based on the latest financial reports, XTL Biopharmaceuticals Ltd (XTLB) holds total assets worth ILA8.55 Million ILA (≈ $22.92K USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
XTL Biopharmaceuticals Ltd - Total Assets Trend (2013–2024)
This chart illustrates how XTL Biopharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data. Also see XTLB market cap for the company's overall valuation and market capitalisation.
XTL Biopharmaceuticals Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
XTL Biopharmaceuticals Ltd's total assets of ILA8.55 Million consist of 15.7% current assets and 84.3% non-current assets. Review XTLB current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 4.3% |
| Accounts Receivable | ILA99.00K | 1.2% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA3.82 Million | 44.6% |
| Goodwill | ILA3.19 Million | 37.4% |
Asset Composition Trend (2013–2024)
This chart illustrates how XTL Biopharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See XTL Biopharmaceuticals Ltd stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: XTL Biopharmaceuticals Ltd's current assets represent 15.7% of total assets in 2024, a decrease from 63.5% in 2013.
- Cash Position: Cash and equivalents constituted 4.3% of total assets in 2024, down from 36.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 81.0% of total assets, an increase from 35.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 44.6% of total assets.
XTL Biopharmaceuticals Ltd Competitors by Total Assets
Key competitors of XTL Biopharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
XTL Biopharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.61 | 9.93 | 28.23 |
| Quick Ratio | 0.61 | 9.93 | 28.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA-867.00K | ILA1.84 Million | ILA6.64 Million |
XTL Biopharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between XTL Biopharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.51 |
| Latest Market Cap to Assets Ratio | 0.53 |
| Asset Growth Rate (YoY) | 252.4% |
| Total Assets | ILA8.55 Million |
| Market Capitalization | $4.49 Million USD |
Valuation Analysis
Below Book Valuation: The market values XTL Biopharmaceuticals Ltd's assets below their book value (0.53x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: XTL Biopharmaceuticals Ltd's assets grew by 252.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for XTL Biopharmaceuticals Ltd (2013–2024)
The table below shows the annual total assets of XTL Biopharmaceuticals Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ILA8.55 Million ≈ $22.92K |
+252.43% |
| 2023-12-31 | ILA2.43 Million ≈ $6.50K |
-42.04% |
| 2022-12-31 | ILA4.19 Million ≈ $11.22K |
-36.75% |
| 2021-12-31 | ILA6.62 Million ≈ $17.74K |
+1.77% |
| 2020-12-31 | ILA6.50 Million ≈ $17.43K |
-9.83% |
| 2019-12-31 | ILA7.21 Million ≈ $19.34K |
-15.90% |
| 2018-12-31 | ILA8.57 Million ≈ $22.99K |
+30.20% |
| 2017-12-31 | ILA6.59 Million ≈ $17.66K |
+118.30% |
| 2016-12-31 | ILA3.02 Million ≈ $8.09K |
-43.32% |
| 2015-12-31 | ILA5.32 Million ≈ $14.27K |
-5.69% |
| 2014-12-31 | ILA5.64 Million ≈ $15.13K |
-29.58% |
| 2013-12-31 | ILA8.02 Million ≈ $21.49K |
-- |
About XTL Biopharmaceuticals Ltd
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company L… Read more